View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2013	Oct. 08, 2013
Document Document And Entity Information [Abstract]
Entity Registrant Name	INTUITIVE SURGICAL INC
Trading Symbol	ISRG
Entity Central Index Key	0001035267
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		38,064,183

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 586.8	$ 553.7
Short-term investments	626.1	770.7
Accounts receivable, net	280.6	370.3
Inventories	200.1	121.5
Prepaids and other current assets	30.0	67.3
Deferred tax assets	9.9	9.3
Total current assets	1,733.5	1,892.8
Property, plant and equipment, net	294.2	241.8
Long-term investments	1,319.4	1,596.1
Long-term deferred tax assets	121.6	87.0
Intangible and other assets, net	91.3	103.4
Goodwill	137.4	138.1
Total assets	3,697.4	4,059.2
Current Liabilities:
Accounts payable	62.0	57.6
Accrued compensation and employee benefits	54.9	104.0
Deferred revenue	192.6	185.7
Other accrued liabilities	57.8	54.3
Total current liabilities	367.3	401.6
Other long-term liabilities	65.8	77.5
Total liabilities	433.1	479.1
Contingencies (Note 5)
Stockholders’ equity
Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; no shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively	0.0	0.0
Common stock, 100.0 shares authorized, $0.001 par value, 38.1 shares and 40.2 shares outstanding as of September 30, 2013 and December 31, 2012, respectively	0.0	0.0
Additional paid-in capital	2,450.7	2,240.1
Retained earnings	813.2	1,333.4
Accumulated other comprehensive income	0.4	6.6
Total stockholders’ equity	3,264.3	3,580.1
Total liabilities and stockholders’ equity	$ 3,697.4	$ 4,059.2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	2,500,000.0	2,500,000.0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, shares authorized (in shares)	100,000,000.0	100,000,000.0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares outstanding (in shares)	38,100,000	40,200,000

Condensed Consolidated Statements of Comprehensive Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue:
Product	$ 397.6	$ 450.0	$ 1,395.0	$ 1,317.5
Service	101.4	87.8	293.9	252.0
Total revenue	499.0	537.8	1,688.9	1,569.5
Cost of revenue:
Product	112.0	119.3	399.2	353.9
Service	30.3	28.4	93.5	83.2
Total cost of revenue	142.3	147.7	492.7	437.1
Gross profit	356.7	390.1	1,196.2	1,132.4
Operating expenses:
Selling, general and administrative	139.3	129.0	426.3	374.1
Research and development	43.2	49.7	126.0	128.3
Total operating expenses	182.5	178.7	552.3	502.4
Income from operations	174.2	211.4	643.9	630.0
Interest and other income, net	3.9	4.3	12.5	12.1
Income before taxes	178.1	215.7	656.4	642.1
Income tax expense	21.3	32.4	151.6	160.4
Net income	$ 156.8	$ 183.3	$ 504.8	$ 481.7
Net income per share:
Basic (in dollars per share)	$ 4.06	$ 4.59	$ 12.75	$ 12.10
Diluted (in dollars per share)	$ 3.99	$ 4.46	$ 12.46	$ 11.72
Shares used in computing net income per share:
Basic (in shares)	38.6	39.9	39.6	39.8
Diluted (in shares)	39.3	41.1	40.5	41.1
Total comprehensive income	$ 159.3	$ 185.5	$ 498.5	$ 486.6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities:
Net income	$ 504.8	$ 481.7
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	32.6	25.2
Amortization of intangible assets	16.6	17.2
Accretion of discounts and amortization of premiums on investments, net	28.6	23.8
Deferred income taxes	(33.8)	(19.3)
Income tax benefits from employee stock option plans	29.7	54.8
Excess tax benefit from stock-based compensation	(31.1)	(54.7)
Share-based compensation expense	127.3	115.0
Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable	89.7	(34.8)
Inventories	(87.9)	(21.0)
Prepaids and other assets	9.7	(5.5)
Accounts payable	4.4	6.9
Accrued compensation and employee benefits	(49.1)	(8.1)
Other liabilities	9.4	6.2
Net cash provided by operating activities	650.9	587.4
Investing activities:
Purchase of investments	(1,130.0)	(1,448.8)
Proceeds from sales of investments	878.1	262.8
Proceeds from maturities of investments	649.8	569.1
Purchase of property, plant and equipment, intellectual property and business	(75.7)	(43.5)
Acquisition of business, net of cash acquired	0.0	(27.6)
Acquisition-related restricted cash	0.0	(15.0)
Net cash provided by (used in) investing activities	322.2	(703.0)
Financing activities:
Proceeds from issuance of common stock, net	137.9	176.5
Excess tax benefit from stock-based compensation	31.1	54.7
Repurchase and retirement of common stock	(1,109.2)	(185.1)
Net cash provided by (used in) financing activities	(940.2)	46.1
Effect of exchange rate changes on cash and cash equivalents	0.2	(0.1)
Net increase (decrease) in cash and cash equivalents	33.1	(69.6)
Cash and cash equivalents, beginning of period	553.7	465.8
Cash and cash equivalents, end of period	$ 586.8	$ 396.2

DESCRIPTION OF BUSINESS	9 Months Ended
DESCRIPTION OF BUSINESS	Sep. 30, 2013
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS	DESCRIPTION OF BUSINESS Intuitive designs, manufactures and markets da Vinci^® Surgical Systems and related instruments and accessories, which taken together, are advanced surgical systems that the Company considers a new generation of surgery. This new generation of surgery, which the Company calls da Vinci surgery, combines the benefits of minimally invasive surgery (“MIS”) for patients with the ease of use, precision and dexterity of open surgery. A da Vinci Surgical System consists of a surgeon’s console, a patient-side cart and a high performance vision system. The da Vinci Surgical System translates a surgeon’s natural hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions, or ports. The da Vinci Surgical System is designed to provide its operating surgeons with intuitive control, range of motion, fine tissue manipulation capability and Three Dimensional (“3-D”), High-Definition (“HD”) vision while simultaneously allowing surgeons to work through the small ports enabled by MIS procedures.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2013
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“financial statements”) of Intuitive Surgical, Inc. and its wholly-owned subsidiaries have been prepared on a consistent basis with the audited Consolidated Financial Statements for the fiscal year ended December 31, 2012 and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”), and, therefore, omit certain information and footnote disclosure necessary to present the financial statements in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”). These financial statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which was filed on February 4, 2013. The results of operations for the first nine months of fiscal 2013 are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods. New Accounting Standards Recently Adopted Effective January 1, 2013, the Company adopted the accounting guidance which requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. The Company elected to present the information in the notes to the Company’s financial statements. In June 2013, the Financial Accounting Standards Board determined that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset for a net operating loss (“NOL”) carryforward or other tax credit carryforward when settlement in this manner is available under applicable tax law. This guidance is effective for the Company’s interim and annual periods beginning January 1, 2014. The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements.

FINANCIAL INSTRUMENTS

9 Months Ended

Sep. 30, 2013

Investments, All Other Investments [Abstract]

FINANCIAL INSTRUMENTS

Cash, Cash Equivalents and Investments

The following tables summarize the amortized cost, gross unrealized gains, gross unrealized losses, and fair value of the Company’s cash and available-for-sale securities by investment category that are recorded as cash and cash equivalents, or short-term or long-term investments as of September 30, 2013 and December 31, 2012 (in millions):



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short- term Investments		Long- term Investments
September 30, 2013
Cash	$	183.1	$	—	$	—		$	183.1	$	183.1	$	—	$	—
Level 1:
Money market funds	368.5		—		—			368.5		368.5		—		—
U.S. Treasuries	84.0		—		(0.4		)	83.6		—		33.7		49.9
Subtotal	452.5		—		(0.4		)	452.1		368.5		33.7		49.9
Level 2:
Commercial paper	121.9		—		—			121.9		33.2		88.7		—
Corporate securities	758.7		2.8		(1.7		)	759.8		—		235.8		524.0
U.S. government agencies	425.0		1.0		(0.8		)	425.2		2.0		103.3		319.9
Non-U.S. government securities	68.0		0.3		(0.2		)	68.1		—		41.4		26.7
Municipal securities	513.8		1.2		(0.3		)	514.7		—		123.2		391.5
Subtotal	1,887.4		5.3		(3.0		)	1,889.7		35.2		592.4		1,262.1
Level 3:
Municipal securities	8.0		—		(0.6		)	7.4		—		—		7.4
Subtotal	8.0		—		(0.6		)	7.4		—		—		7.4
Total assets measured at fair value	$	2,531.0	$	5.3	$	(4.0	)	$	2,532.3	$	586.8	$	626.1	$	1,319.4



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short- term Investments		Long- term Investments
December 31, 2012
Cash	$	89.7	$	—	$	—		$	89.7	$	89.7	$	—	$	—
Level 1:
Money market funds	388.1		—		—			388.1		388.1		—		—
U.S. Treasuries & corporate equity securities	179.2		0.2		—			179.4		—		155.4		24.0
Subtotal	567.3		0.2		—			567.5		388.1		155.4		24.0
Level 2:
Commercial paper	157.4		—		—			157.4		75.9		81.5		—
Corporate securities	952.1		5.8		(0.4		)	957.5		—		274.6		682.9
U.S. government agencies	636.9		2.6		—			639.5		—		133.6		505.9
Non-U.S. government securities	90.8		0.5		—			91.3		—		21.8		69.5
Municipal securities	409.3		1.1		(0.2		)	410.2		—		103.8		306.4
Subtotal	2,246.5		10.0		(0.6		)	2,255.9		75.9		615.3		1,564.7
Level 3:
Municipal securities	8.0		—		(0.6		)	7.4		—		—		7.4
Subtotal	8.0		—		(0.6		)	7.4		—		—		7.4
Total assets measured at fair value	$	2,911.5	$	10.2	$	(1.2	)	$	2,920.5	$	553.7	$	770.7	$	1,596.1

The following table summarizes the contractual maturities of the Company’s cash equivalents and available-for-sale securities, excluding corporate equity securities, at September 30, 2013 (in millions):



	Amortized Cost		Fair Value
Mature in less than one year	$	1,028.6	$	1,029.8
Mature in one to five years	1,311.3		1,312.0
Mature in after five years	8.0		7.4
Total	$	2,347.9	$	2,349.2

During the three and nine months ended September 30, 2013, net realized gains recognized on the sale of investments were approximately $0.6 million and $0.7 million, respectively. Net realized losses recognized on the sale of investments during the three and nine months ended September 30, 2012 were approximately $0.2 million and $1.7 million, respectively. As of September 30, 2013 and December 31, 2012, net unrealized gains of $1.7 million and $6.2 million, respectively, were included in accumulated other comprehensive income in the accompanying unaudited Condensed Consolidated Balance Sheets.

There have been no transfers between Level 1 and Level 2 measurements during the nine months ended September 30, 2013, and there were no changes in the Company’s valuation technique. Level 3 assets consist of municipal bonds with auction rate securities (“ARS”) whose underlying assets are student loans which are generally backed by the federal government. Since the auctions for these securities have continued to fail since February 2008, these investments are not currently trading and therefore do not have a readily determinable fair value. The Company has valued its ARS using a discounted cash flow model utilizing unobservable inputs including estimates of interest rates, timing and amount of cash flows, credit and liquidity premiums and expected holding periods of the ARS.

Foreign currency derivatives

The objective of the Company’s hedging program is to mitigate the impact of changes in currency exchange rates on net cash flow from foreign currency denominated sales and intercompany balances and other monetary assets or liabilities denominated in currencies other than the U.S. dollar. The Company has $3.0 million of derivative liabilities recorded as other accrued liabilities in the unaudited Condensed Consolidated Balance Sheets at September 30, 2013, compared to $2.7 million of derivative liabilities recorded as other accrued liabilities in the Condensed Consolidated Balance Sheets at December 31, 2012. The derivative liabilities are measured using Level 2 fair value inputs.

Cash Flow Hedges

The Company enters into currency forward contracts as cash flow hedges to hedge certain forecasted revenue transactions denominated in currencies other than the U.S. dollar, primarily the European Euro (“EUR”) and the Korean Won (“KRW”).

As of September 30, 2013, the Company had notional amounts of EUR 36.9 million and KRW 1.8 billion of outstanding currency forward contracts entered into to hedge EUR and KRW denominated sales, compared to EUR 20.0 million and KRW 4.4 billion of outstanding currency forward contracts at December 31, 2012. The net gains (losses) reclassified to revenue related to the hedged revenue transactions for the three and nine months ended September 30, 2013 and 2012 were not significant. Other impacts of derivative instruments designated as cash flow hedges were not significant for the three and nine months ended September 30, 2013 and 2012.

Other Derivatives Not Designated as Hedging Instruments:

Other derivatives not designated as hedging instruments consist primarily of forward contracts that the Company uses to hedge intercompany balances and other monetary assets or liabilities denominated in currencies other than the U.S. dollar, primarily the EUR, the British Pound (“GBP”), the Swiss Franc (“CHF”), Japanese Yen (“JPY”) and the KRW. Accordingly, any gains or losses from changes in the fair value of the forward contracts are recorded in interest and other income, net. The gains and losses on these forward contracts generally offset the gains and losses associated with the underlying assets and liabilities, which are also recorded in interest and other income, net. The duration of the forward contracts for hedging the Company’s balance sheet exposure is approximately one month.

Derivative instruments used to hedge against balance sheet foreign currency exposures at the end of each period were as follows (in millions):



	Three Months Ended September 30,					Nine Months Ended September 30,
	2013			2012		2013			2012
Recognized gains (losses) in interest and other income, net	$	(2.6	)	$	—	$	(1.8	)	$	0.6
Foreign exchange gains (losses) related to re-measurement	$	2.4		$	0.2	$	1.0		$	(0.4	)

The notional amounts for derivative instruments provide one measure of the transaction volume. Total gross notional amounts (in local currency) for derivatives (recorded at fair value) outstanding at the end of each period were as follows (in millions):



	September 30, 2013	December 31, 2012
European Euro	31.6	37.6
Korean Won	12,204.2	4,600.0
British Pound	7.0	5.4
Swiss Franc	—	1.0
Japanese Yen	70.0	—

BALANCE SHEET DETAILS

9 Months Ended

Sep. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BALANCE SHEET DETAILS

Inventories

The following table summarizes the Company’s inventories as of September 30, 2013 and December 31, 2012 (in millions):



	September 30, 2013		December 31, 2012
Inventories:
Raw materials	$	59.1	$	41.2
Work-in-process	6.8		4.4
Finished goods	134.2		75.9
Total inventories	$	200.1	$	121.5

CONTINGENCIES	9 Months Ended
CONTINGENCIES	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES On August 6, 2010, a purported class action lawsuit entitled Perlmutter v. Intuitive Surgical et al., No. CV10-3451, was filed against seven of the Company’s current and former officers and directors in the United States District Court for the Northern District of California. The lawsuit seeks unspecified damages on behalf of a putative class of persons who purchased or otherwise acquired the Company’s common stock between February 1, 2008 and January 7, 2009. The complaint alleges that the defendants violated federal securities laws by making allegedly false and misleading statements and omitting certain material facts in the Company’s filings with the Securities and Exchange Commission. On February 15, 2011, the Police Retirement System of St. Louis was appointed lead plaintiff in the case pursuant to the Private Securities Litigation Reform Act of 1995. An amended complaint was filed on April 15, 2011, making allegations substantially similar to the allegations described above. On May 23, 2011, the Company filed a motion to dismiss the amended complaint. On August 10, 2011, that motion was granted and the action was dismissed; the plaintiffs were given 30 days to file an amended complaint. On September 12, 2011, plaintiffs filed their amended complaint. The allegations contained therein are substantially similar to the allegations in the prior complaint. The Company filed a motion to dismiss the amended complaint. A hearing occurred on February 16, 2012, and on May 22, 2012 the Company’s motion was granted. The complaint was dismissed with prejudice, and a final judgment was entered in the Company’s favor on June 1, 2012. On June 20, 2012, plaintiffs filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. The appeal is styled Police Retirement System of St. Louis v. Intuitive Surgical, Inc. et al., No. 12-16430. Plaintiffs filed their opening brief on September 28, 2012. The Company filed an answering brief on November 13, 2012, and plaintiffs filed a reply brief on December 17, 2012. No oral argument date has been set, and the appeal remains pending. On August 19, 2010, an alleged stockholder caused a purported stockholder’s derivative lawsuit entitled Himmel v. Smith et al., No. 1-10-CV-180416, to be filed in the Superior Court of California for the County of Santa Clara naming the Company as a nominal defendant, and naming 14 of the Company’s current and former officers and directors as defendants. The lawsuit seeks to recover, for the Company’s benefit, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and/or omissions made in connection with the Company’s financial reporting for the period between February 1, 2008 and January 7, 2009. It also seeks a series of changes to the Company’s corporate governance policies and an award of attorneys’ fees. On September 15, 2010, another purported stockholder filed an essentially identical lawsuit entitled Applebaum v. Guthart et al., No. 1-10-CV-182645, in the same court against 15 of the Company’s current and former officers and directors. On October 5, 2010, the court ordered that the two cases be consolidated for all purposes. By agreement with the plaintiffs, all activity in the case has been stayed pending the results of the appeal in the purported shareholder class action lawsuit discussed above. On April 26, 2013, a purported class action lawsuit entitled Abrams v. Intuitive Surgical et al., No. 5-13-cv-1920, was filed against nine of the Company’s current and former officers and directors in the United States District Court for the Northern District of California. A substantially identical complaint, entitled Adel v. Intuitive Surgical, et al., No. 5:13-cv-02365, was filed in the same court against the same defendants on May 24, 2013. The Adel case was voluntarily dismissed without prejudice on August 20, 2013. The Abrams lawsuit seeks unspecified damages on behalf of a putative class of persons who purchased or otherwise acquired the Company’s common stock between October 19, 2011 and April 18, 2013. The complaint alleges that the defendants violated federal securities laws by making allegedly false and misleading statements and omitting certain material facts in the Company’s filings with the Securities and Exchange Commission. Motions seeking appointment as lead plaintiff in the Abrams case were filed by two parties on June 25, 2013. One of those motions was subsequently withdrawn. The remaining motion is scheduled to be heard on November 22, 2013. By agreement with the plaintiff in the Abrams action, no response to the complaint is required until after a lead plaintiff is appointed by the Court and that duly appointed lead plaintiff files a consolidated complaint or informs us that it has chosen to proceed with the complaint already on file. Also by agreement with plaintiff, the lead plaintiff filed a consolidated complaint on October 15, 2013, and the Company must respond by December 16, 2013. The Company is currently named as a defendant in about 50 individual product liability lawsuits filed in various state and federal courts by plaintiffs who allege that they underwent surgical procedures that utilized the da Vinci Surgical System and sustained a variety of personal injuries and, in some cases, death as a result of such surgery. In addition, the Company has been named as a defendant in a purported class action filed in Louisiana state court seeking damages on behalf of all patients who were allegedly injured by the da Vinci Surgical System at a single hospital in Louisiana. The cases raise a variety of allegations including, to varying degrees, that the plaintiffs' injuries resulted from purported defects in the da Vinci Surgical System and/or failure on the Company’s part to provide adequate training resources to the healthcare professionals who performed plaintiffs’ surgeries. The cases further allege that the Company failed to adequately disclose and/or misrepresented the potential risks and/or benefits of the da Vinci Surgical System. Plaintiffs also assert a variety of causes of action, including for example, strict liability based on purported design defects, negligence, fraud, breach of express and implied warranties, unjust enrichment, and loss of consortium. Plaintiffs seek recovery for alleged personal injuries and, in many cases, punitive damages. Except for a few cases, including the Taylor case described below, these cases generally are in the early stages of pretrial activity. Plaintiffs’ attorneys are engaged in well-funded national advertising campaigns soliciting clients who have undergone da Vinci surgery and claim to have suffered an injury. The plaintiffs’ attorneys are now alleging that Intuitive Surgical is liable for those injuries under products liability theories. The Company has seen a substantial increase in these claims; however, the Company has not received detailed information regarding many of these claims. In an effort to provide an orderly process for evaluating claims before they result in costly litigation, the Company has entered into tolling agreements with certain plaintiffs’ counsel acting on behalf of such claimants. The tolling agreements provide that the statute of limitations for each individual will be tolled for a period of three to six months in exchange for the individual’s agreement that, if he or she ultimately files a lawsuit, it will be filed in certain agreed upon venues. The tolling agreements provide the parties and their legal counsel with additional time to evaluate the claims, and to explore whether the claims have merit and whether they can be resolved without litigation. The Company does not currently know how many individuals will ultimately file lawsuits or decide not to pursue their claims, nor is the Company able at this time to estimate the financial impact of their claims or predict the final disposition of such claims. Based on currently available information, the Company believes that it has meritorious defenses in the above matters and intends to assert them vigorously. In February 2011, the Company was named as a defendant in a product liability action that had originally been filed in Washington State Superior Court for Kitsap County against the healthcare providers and hospital involved in the plaintiff’s decedent’s surgery (Josette Taylor, as Personal Representative of the Estate of Fred E. Taylor, deceased; and on behalf of the Estate of Fred E. Taylor v. Intuitive Surgical, Inc., No. 09-2-03136-5). In Taylor, plaintiff asserted wrongful death and product liability claims against the Company, generally alleging that the decedent died four years after surgery as a result of injuries purportedly suffered during the surgery, which was conducted with the use of the da Vinci Surgical System. The plaintiff in Taylor asserted that such injuries were caused, in whole or in part, by the Company’s purported failure to properly train, warn, and instruct the surgeon. The lawsuit sought unspecified damages for past medical expenses, pain and suffering, loss of consortium as well as punitive damages. A trial commenced in the action on April 15, 2013. On May 23, 2013, the jury returned a defense verdict, finding that the Company was not negligent. Judgment was entered in favor of Intuitive Surgical on June 7, 2013. Plaintiff has filed a notice of appeal. Due to the uncertainty surrounding the litigation process, the Company is unable, at this time, to reasonably predict the ultimate outcome of the above matters or estimate the possible loss or range of losses which may be incurred. Based on currently available information, the Company believes that it has meritorious defenses in the above matters and intends to assert them vigorously. The Company is also a party to various other legal actions that have arisen in the ordinary course of its business. The Company does not believe that any of these other legal actions will have a material adverse impact on its business, financial position or results of operations.

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2013

Equity [Abstract]

STOCKHOLDERS' EQUITY

STOCKHOLDERS’ EQUITY

Share Repurchase Program

The following table provides the share repurchase activities during the three and nine months ended September 30, 2013 and 2012 (in millions, except per share amounts):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
Shares repurchased	1.8		0.3		2.6		0.4
Average price per share	$	398.87	$	495.09	$	429.09	$	497.28
Value of shares repurchased	$	693.8	$	169.8	$	1,109.2	$	185.1

On July 25, 2013 and March 20, 2013, the Company’s Board of Directors (the “Board”) authorized additional stock repurchases of $779 million and $1.0 billion, respectively. As of September 30, 2013, the remaining amount of share repurchases authorized by the Board was approximately $1.0 billion.

On July 29, 2013, in connection with the stock repurchase authorization, the Company entered into an accelerated share repurchase program (the “ASR Program”) with Goldman, Sachs & Co. (“Goldman”) to repurchase $500 million of the Company’s common stock. Under the ASR Program, the Company paid an initial purchase price of $500 million to Goldman and received an initial delivery of approximately 1.2 million shares of its common stock. On September 11, 2013, Goldman exercised its early termination option under the ASR Program and the pricing period was closed. The settlement price was $385.16 per share. Based on this settlement price, the final number of shares repurchased by the Company and delivered by Goldman under the ASR Program was 1.3 million shares. The Company received the additional 0.1 million shares from Goldman on September 16, 2013 to settle the difference between the initial share delivery and the total number of shares repurchased.

In addition to the ASR Program, the Company repurchased an additional 0.5 million shares of the Company’s common stock during the three months ended September 30, 2013. All of these shares were repurchased in the open market.

All common stock repurchased has been retired as of September 30, 2013. As a result of the stock repurchases made during the three months ended September 30, 2013, the Company reduced common stock and APIC by an aggregate of $57.4 million and charged $636.4 million to retained earnings.

Accumulated Other Comprehensive Income

The components of accumulated other comprehensive income, net of tax, for the three and nine months ended September 30, 2013 and 2012 are as follows (in millions):



	Three Months Ended September 30, 2013
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for- Sale Securities			Foreign Currency Translation Gains (Losses)		Total
Beginning balance	$	0.6		$	(2.8	)	$	0.1	$	(2.1	)
Other comprehensive income before reclassifications	(3.0		)	3.9			0.5		1.4
Reclassified from accumulated other comprehensive income	0.5			0.6			—		1.1
Net current-period other comprehensive income	(2.5		)	4.5			0.5		2.5
Ending balance	$	(1.9	)	$	1.7		$	0.6	$	0.4

	Three Months Ended September 30, 2012
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for- Sale Securities			Foreign Currency Translation Gains (Losses)		Total
Beginning balance	$	0.3		$	3.3		$	—	$	3.6
Other comprehensive income before reclassifications	(1.7		)	3.5			0.1		1.9
Reclassified from accumulated other comprehensive income	0.2			0.1			—		0.3
Net current-period other comprehensive income	(1.5		)	3.6			0.1		2.2
Ending balance	$	(1.2	)	$	6.9		$	0.1	$	5.8



	Nine Months Ended September 30, 2013
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for- Sale Securities			Foreign Currency Translation Gains (Losses)			Total
Beginning balance	$	—		$	6.2		$	0.4		$	6.6
Other comprehensive income before reclassifications	(1.4		)	(5.4		)	0.2			(6.6		)
Reclassified from accumulated other comprehensive income	(0.5		)	0.9			—			0.4
Net current-period other comprehensive income	(1.9		)	(4.5		)	0.2			(6.2		)
Ending balance	$	(1.9	)	$	1.7		$	0.6		$	0.4

	Nine Months Ended September 30, 2012
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for- Sale Securities			Foreign Currency Translation Gains (Losses)			Total
Beginning balance	$	—		$	1.1		$	(0.2	)	$	0.9
Other comprehensive income before reclassifications	(1.0		)	5.5			0.3			4.8
Reclassified from accumulated other comprehensive income	(0.2		)	0.3			—			0.1
Net current-period other comprehensive income	(1.2		)	5.8			0.3			4.9
Ending balance	$	(1.2	)	$	6.9		$	0.1		$	5.8

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

SHARE-BASED COMPENSATION

9 Months Ended

Sep. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHARE-BASED COMPENSATION

Stock Option Plans

2009 Employment Commencement Incentive Plan

In January 2013, the Board amended and restated the 2009 Employment Commencement Incentive Plan (“2009 Plan”) to provide for an increase in the number of shares of common stock authorized for issuance pursuant to awards granted under the 2009 Plan from 730,000 to 855,000. In May 2013, the Board amended and restated the 2009 Plan to provide for an additional increase in the number of shares of common stock authorized for issuance pursuant to awards granted under the 2009 Plan from 855,000 to 1,155,000.

2010 Incentive Award Plan

On April 25, 2013, the Shareholders approved an amended and restated 2010 Incentive Award Plan (“2010 Plan”) to provide for an increase in the number of shares of common stock reserved for issuance from 3,650,000 to 4,850,000.

A summary of stock option activity under all stock plans for the nine months ended September 30, 2013 is presented as follows (in millions, except per share amounts):



			Stock Options Outstanding
	Shares Available for Grant		Number Outstanding		Weighted Average Exercise Price Per Share
Balance at December 31, 2012	1.7		4.8		$	340.83
Options authorized	1.6		—		—
Options granted	(1.5	)	1.5		473.68
Options exercised	—		(0.4	)	253.53
Options forfeited/expired	0.1		(0.2	)	456.31
Balance at September 30, 2013	1.9		5.7		$	379.15

As of September 30, 2013, options to purchase an aggregate of 3.1 million shares of common stock were exercisable at a weighted-average price of $312.11 per share.

Employee Stock Purchase Plan

Under the Employee Stock Purchase Plan (“ESPP”), employees purchased approximately 37.7 thousand shares for $12.4 million and 47.6 thousand shares for $13.9 million during the three months ended September 30, 2013 and 2012, respectively. Employees purchased approximately 92.2 thousand shares for $28.8 million and 96.8 thousand shares for $27.8 million during the nine months ended September 30, 2013 and 2012, respectively.

Share-based Compensation

The following table summarizes share-based compensation expense for the three and nine months ended September 30, 2013 and 2012 (in millions):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
Cost of sales - products	$	5.2	$	4.3	$	13.2	$	10.6
Cost of sales - services	3.6		4.1		9.5		9.6
Total cost of sales	8.8		8.4		22.7		20.2
Selling, general and administrative	30.6		28.2		76.6		69.7
Research and development	11.0		10.7		28.0		25.1
Share-based compensation expense before income taxes	50.4		47.3		127.3		115.0
Income tax benefit	16.5		14.9		41.1		36.0
Share-based compensation expense after income taxes	$	33.9	$	32.4	$	86.2	$	79.0

The fair value of each option grant and the fair value of the option component of the ESPP shares were estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions, assuming no expected dividends:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012
Stock Options
Average risk free interest rate	1.5		%	0.8		%	1.2		%	0.8		%
Average expected term (in years)	4.5			4.1			4.5			4.3
Average expected volatility	31		%	35		%	30		%	33		%
Weighted average fair value at grant date	$	110.81		$	148.05		$	126.87		$	145.60
ESPP
Average risk free interest rate	0.2		%	0.2		%	0.2		%	0.2		%
Average expected term (in years)	1.3			1.3			1.3			1.3
Average expected volatility	35		%	32		%	34		%	32		%
Weighted average fair value at grant date	$	115.84		$	143.36		$	153.33		$	138.61

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2013
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income tax expense for the three month period ended September 30, 2013 was $21.3 million, or 12.0% of pre-tax income, compared with $32.4 million, or 15.0% of pre-tax income for the three month period ended September 30, 2012. Income tax expense for the nine month period ended September 30, 2013 was $151.6 million, or 23.1% of pre-tax income, compared with $160.4 million, or 25.0% of pre-tax income for the nine month period ended September 30, 2012. The Company's effective tax rates for these periods differ from the U.S. federal statutory rate of 35% due primarily to the effect of the reversal of unrecognized tax benefits, and associated interest, in connection with the expiration of certain statutes of limitations, and income earned by certain of the Company’s overseas entities being taxed at rates lower than the federal statutory rate, partially offset by state income taxes and non-deductible stock option expenses. The Company intends to indefinitely reinvest outside the U.S. all of its undistributed foreign earnings that were not previously subject to U.S. tax. The income tax provision for the three month periods ended September 30, 2013 and 2012 included discrete benefits of $26.2 million and $35.1 million, respectively, primarily related to the reversal of unrecognized tax benefits, and associated interest, in connection with the expiration of certain statutes of limitations in multiple jurisdictions. The income tax provision for the nine month period ended September 30, 2013 reflected a net tax benefit of $7.5 million related to 2012 federal research and development (“R&D”) credit which was retroactively reinstated during the three month period ended March 31, 2013. No federal R&D credit benefit was recorded in the income tax provision for the nine month period ended September 30, 2012. The income tax provision for the nine month period ended September 30, 2012 included a discrete recognition of certain previously unrecognized tax benefits as a result of new IRS guidance issued in the first quarter of 2012. As of September 30, 2013, the Company had total gross unrecognized tax benefits of approximately $77.6 million compared with approximately $88.0 million as of December 31, 2012, representing a net decrease of approximately $10.4 million for the nine months ended September 30, 2013. The net decrease is primarily related to the above mentioned reversal of previously unrecognized tax benefits as a result of the expiration of certain statutes of limitations in multiple jurisdictions, partially offset by increases during the first nine months of 2013 related to other uncertain tax positions. Of the total gross unrecognized tax benefits, $76.0 million as of September 30, 2013, if recognized, would reduce the effective tax rate in the period of recognition. Gross interest related to unrecognized tax benefit accrued was approximately $1.9 million and $3.2 million as of September 30, 2013 and December 31, 2012, respectively, representing a decrease of $1.3 million as a result of the expiration of statutes of limitations, partially offset by increases related to other unrecognized tax positions. The Company files federal, state and foreign income tax returns in many jurisdictions in the U.S. and internationally. Generally, years before 2010 are closed for most significant jurisdictions except for California, for which all years since inception remain open due to utilization in open years of net operating losses and R&D credit carryovers or longer statutes of limitations. Certain of the Company’s unrecognized tax benefits could reverse based on the normal expiration of various statutes of limitations, which could affect the Company’s effective tax rate in the period in which they reverse. The Company is subject to the examination of its income tax returns by the Internal Revenue Service and other tax authorities. The outcome of these audits cannot be predicted with certainty. Management regularly assesses the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of the Company’s provision for income taxes. If any issues addressed in the Company’s tax audits are resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.

NET INCOME PER SHARE

9 Months Ended

Sep. 30, 2013

Earnings Per Share [Abstract]

NET INCOME PER SHARE

The following table presents the computation of basic and diluted net income per share for the three and nine months ended September 30, 2013 and 2012 (in millions, except per share amounts):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
Numerator:
Net income	$	156.8	$	183.3	$	504.8	$	481.7
Denominator:
Weighted-average shares outstanding used in basic calculation	38.6		39.9		39.6		39.8
Add: Dilutive effect of potential common shares	0.7		1.2		0.9		1.3
Weighted-average shares used in computing diluted net income per share	39.3		41.1		40.5		41.1
Net income per share:
Basic	$	4.06	$	4.59	$	12.75	$	12.10
Diluted	$	3.99	$	4.46	$	12.46	$	11.72

Employee stock options to purchase approximately 2.6 million and 1.1 million weighted-average shares for the three months ended September 30, 2013 and 2012, respectively, and approximately 2.1 million and 0.8 million weighted-average shares for the nine months ended September 30, 2013 and 2012, respectively, were outstanding, but were not included in the computation of diluted net income per share because the effect of including such shares would have been anti-dilutive.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2013
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“financial statements”) of Intuitive Surgical, Inc. and its wholly-owned subsidiaries have been prepared on a consistent basis with the audited Consolidated Financial Statements for the fiscal year ended December 31, 2012 and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”), and, therefore, omit certain information and footnote disclosure necessary to present the financial statements in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”). These financial statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which was filed on February 4, 2013. The results of operations for the first nine months of fiscal 2013 are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods.
New Accounting Standards Recently Adopted	New Accounting Standards Recently Adopted Effective January 1, 2013, the Company adopted the accounting guidance which requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. The Company elected to present the information in the notes to the Company’s financial statements. In June 2013, the Financial Accounting Standards Board determined that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset for a net operating loss (“NOL”) carryforward or other tax credit carryforward when settlement in this manner is available under applicable tax law. This guidance is effective for the Company’s interim and annual periods beginning January 1, 2014. The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements.

FINANCIAL INSTRUMENTS (Tables)

9 Months Ended

Sep. 30, 2013

Investments, All Other Investments [Abstract]

Summary of Cash and Available-For-Sale Securities



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short- term Investments		Long- term Investments
September 30, 2013
Cash	$	183.1	$	—	$	—		$	183.1	$	183.1	$	—	$	—
Level 1:
Money market funds	368.5		—		—			368.5		368.5		—		—
U.S. Treasuries	84.0		—		(0.4		)	83.6		—		33.7		49.9
Subtotal	452.5		—		(0.4		)	452.1		368.5		33.7		49.9
Level 2:
Commercial paper	121.9		—		—			121.9		33.2		88.7		—
Corporate securities	758.7		2.8		(1.7		)	759.8		—		235.8		524.0
U.S. government agencies	425.0		1.0		(0.8		)	425.2		2.0		103.3		319.9
Non-U.S. government securities	68.0		0.3		(0.2		)	68.1		—		41.4		26.7
Municipal securities	513.8		1.2		(0.3		)	514.7		—		123.2		391.5
Subtotal	1,887.4		5.3		(3.0		)	1,889.7		35.2		592.4		1,262.1
Level 3:
Municipal securities	8.0		—		(0.6		)	7.4		—		—		7.4
Subtotal	8.0		—		(0.6		)	7.4		—		—		7.4
Total assets measured at fair value	$	2,531.0	$	5.3	$	(4.0	)	$	2,532.3	$	586.8	$	626.1	$	1,319.4



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short- term Investments		Long- term Investments
December 31, 2012
Cash	$	89.7	$	—	$	—		$	89.7	$	89.7	$	—	$	—
Level 1:
Money market funds	388.1		—		—			388.1		388.1		—		—
U.S. Treasuries & corporate equity securities	179.2		0.2		—			179.4		—		155.4		24.0
Subtotal	567.3		0.2		—			567.5		388.1		155.4		24.0
Level 2:
Commercial paper	157.4		—		—			157.4		75.9		81.5		—
Corporate securities	952.1		5.8		(0.4		)	957.5		—		274.6		682.9
U.S. government agencies	636.9		2.6		—			639.5		—		133.6		505.9
Non-U.S. government securities	90.8		0.5		—			91.3		—		21.8		69.5
Municipal securities	409.3		1.1		(0.2		)	410.2		—		103.8		306.4
Subtotal	2,246.5		10.0		(0.6		)	2,255.9		75.9		615.3		1,564.7
Level 3:
Municipal securities	8.0		—		(0.6		)	7.4		—		—		7.4
Subtotal	8.0		—		(0.6		)	7.4		—		—		7.4
Total assets measured at fair value	$	2,911.5	$	10.2	$	(1.2	)	$	2,920.5	$	553.7	$	770.7	$	1,596.1

Summary of Contractual Maturities of Cash Equivalents and Available-For-Sale Investments



	Amortized Cost		Fair Value
Mature in less than one year	$	1,028.6	$	1,029.8
Mature in one to five years	1,311.3		1,312.0
Mature in after five years	8.0		7.4
Total	$	2,347.9	$	2,349.2

Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures

Derivative instruments used to hedge against balance sheet foreign currency exposures at the end of each period were as follows (in millions):



	Three Months Ended September 30,					Nine Months Ended September 30,
	2013			2012		2013			2012
Recognized gains (losses) in interest and other income, net	$	(2.6	)	$	—	$	(1.8	)	$	0.6
Foreign exchange gains (losses) related to re-measurement	$	2.4		$	0.2	$	1.0		$	(0.4	)

Gross Notional Amounts for Outstanding Derivatives

Total gross notional amounts (in local currency) for derivatives (recorded at fair value) outstanding at the end of each period were as follows (in millions):



	September 30, 2013	December 31, 2012
European Euro	31.6	37.6
Korean Won	12,204.2	4,600.0
British Pound	7.0	5.4
Swiss Franc	—	1.0
Japanese Yen	70.0	—

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

BALANCE SHEET DETAILS (Tables)

9 Months Ended

Sep. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Inventory Details

The following table summarizes the Company’s inventories as of September 30, 2013 and December 31, 2012 (in millions):



	September 30, 2013		December 31, 2012
Inventories:
Raw materials	$	59.1	$	41.2
Work-in-process	6.8		4.4
Finished goods	134.2		75.9
Total inventories	$	200.1	$	121.5

STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2013

Equity [Abstract]

Schedule of Stock Repurchase Activities

The following table provides the share repurchase activities during the three and nine months ended September 30, 2013 and 2012 (in millions, except per share amounts):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
Shares repurchased	1.8		0.3		2.6		0.4
Average price per share	$	398.87	$	495.09	$	429.09	$	497.28
Value of shares repurchased	$	693.8	$	169.8	$	1,109.2	$	185.1

Components of Accumulated Other Comprehensive Income, Net of Tax

The components of accumulated other comprehensive income, net of tax, for the three and nine months ended September 30, 2013 and 2012 are as follows (in millions):



	Three Months Ended September 30, 2013
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for- Sale Securities			Foreign Currency Translation Gains (Losses)		Total
Beginning balance	$	0.6		$	(2.8	)	$	0.1	$	(2.1	)
Other comprehensive income before reclassifications	(3.0		)	3.9			0.5		1.4
Reclassified from accumulated other comprehensive income	0.5			0.6			—		1.1
Net current-period other comprehensive income	(2.5		)	4.5			0.5		2.5
Ending balance	$	(1.9	)	$	1.7		$	0.6	$	0.4

	Three Months Ended September 30, 2012
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for- Sale Securities			Foreign Currency Translation Gains (Losses)		Total
Beginning balance	$	0.3		$	3.3		$	—	$	3.6
Other comprehensive income before reclassifications	(1.7		)	3.5			0.1		1.9
Reclassified from accumulated other comprehensive income	0.2			0.1			—		0.3
Net current-period other comprehensive income	(1.5		)	3.6			0.1		2.2
Ending balance	$	(1.2	)	$	6.9		$	0.1	$	5.8



	Nine Months Ended September 30, 2013
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for- Sale Securities			Foreign Currency Translation Gains (Losses)			Total
Beginning balance	$	—		$	6.2		$	0.4		$	6.6
Other comprehensive income before reclassifications	(1.4		)	(5.4		)	0.2			(6.6		)
Reclassified from accumulated other comprehensive income	(0.5		)	0.9			—			0.4
Net current-period other comprehensive income	(1.9		)	(4.5		)	0.2			(6.2		)
Ending balance	$	(1.9	)	$	1.7		$	0.6		$	0.4

	Nine Months Ended September 30, 2012
	Gains (Losses) on Hedge Instruments			Unrealized Gains (Losses) on Available-for- Sale Securities			Foreign Currency Translation Gains (Losses)			Total
Beginning balance	$	—		$	1.1		$	(0.2	)	$	0.9
Other comprehensive income before reclassifications	(1.0		)	5.5			0.3			4.8
Reclassified from accumulated other comprehensive income	(0.2		)	0.3			—			0.1
Net current-period other comprehensive income	(1.2		)	5.8			0.3			4.9
Ending balance	$	(1.2	)	$	6.9		$	0.1		$	5.8

SHARE-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Stock Option Activity Under All Stock Plans

A summary of stock option activity under all stock plans for the nine months ended September 30, 2013 is presented as follows (in millions, except per share amounts):



			Stock Options Outstanding
	Shares Available for Grant		Number Outstanding		Weighted Average Exercise Price Per Share
Balance at December 31, 2012	1.7		4.8		$	340.83
Options authorized	1.6		—		—
Options granted	(1.5	)	1.5		473.68
Options exercised	—		(0.4	)	253.53
Options forfeited/expired	0.1		(0.2	)	456.31
Balance at September 30, 2013	1.9		5.7		$	379.15

Summary of Share-Based Compensation Expense

The following table summarizes share-based compensation expense for the three and nine months ended September 30, 2013 and 2012 (in millions):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
Cost of sales - products	$	5.2	$	4.3	$	13.2	$	10.6
Cost of sales - services	3.6		4.1		9.5		9.6
Total cost of sales	8.8		8.4		22.7		20.2
Selling, general and administrative	30.6		28.2		76.6		69.7
Research and development	11.0		10.7		28.0		25.1
Share-based compensation expense before income taxes	50.4		47.3		127.3		115.0
Income tax benefit	16.5		14.9		41.1		36.0
Share-based compensation expense after income taxes	$	33.9	$	32.4	$	86.2	$	79.0

Schedule of Estimated Fair Value of the Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions



	Three Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012
Stock Options
Average risk free interest rate	1.5		%	0.8		%	1.2		%	0.8		%
Average expected term (in years)	4.5			4.1			4.5			4.3
Average expected volatility	31		%	35		%	30		%	33		%
Weighted average fair value at grant date	$	110.81		$	148.05		$	126.87		$	145.60
ESPP
Average risk free interest rate	0.2		%	0.2		%	0.2		%	0.2		%
Average expected term (in years)	1.3			1.3			1.3			1.3
Average expected volatility	35		%	32		%	34		%	32		%
Weighted average fair value at grant date	$	115.84		$	143.36		$	153.33		$	138.61

NET INCOME PER SHARE (Tables)

9 Months Ended

Sep. 30, 2013

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Income Per Share

The following table presents the computation of basic and diluted net income per share for the three and nine months ended September 30, 2013 and 2012 (in millions, except per share amounts):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
Numerator:
Net income	$	156.8	$	183.3	$	504.8	$	481.7
Denominator:
Weighted-average shares outstanding used in basic calculation	38.6		39.9		39.6		39.8
Add: Dilutive effect of potential common shares	0.7		1.2		0.9		1.3
Weighted-average shares used in computing diluted net income per share	39.3		41.1		40.5		41.1
Net income per share:
Basic	$	4.06	$	4.59	$	12.75	$	12.10
Diluted	$	3.99	$	4.46	$	12.46	$	11.72

FINANCIAL INSTRUMENTS - Summary of Cash and Available-For-Sale Securities (Detail) - USD ($) $ in Millions	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 2,531.0	$ 2,911.5
Gross Unrealized Gains	5.3	10.2
Gross Unrealized Losses	(4.0)	(1.2)
Fair Value	2,532.3	2,920.5
Cash and Cash Equivalents	586.8	553.7	$ 396.2	$ 465.8
Short- term Investments	626.1	770.7
Long- term Investments	1,319.4	1,596.1
Cash
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	183.1	89.7
Fair Value	183.1	89.7
Cash and Cash Equivalents	183.1	89.7
Level 1
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	452.5	567.3
Gross Unrealized Gains	0.0	0.2
Gross Unrealized Losses	(0.4)	0.0
Fair Value	452.1	567.5
Cash and Cash Equivalents	368.5	388.1
Short- term Investments	33.7	155.4
Long- term Investments	49.9	24.0
Level 1 \| Money market funds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	368.5	388.1
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	368.5	388.1
Cash and Cash Equivalents	368.5	388.1
Level 1 \| U.S. Treasuries
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	84.0
Gross Unrealized Gains	0.0
Gross Unrealized Losses	(0.4)
Fair Value	83.6
Cash and Cash Equivalents	0.0
Short- term Investments	33.7
Long- term Investments	49.9
Level 1 \| U.S. Treasuries & corporate equity securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		179.2
Gross Unrealized Gains		0.2
Gross Unrealized Losses		0.0
Fair Value		179.4
Cash and Cash Equivalents		0.0
Short- term Investments		155.4
Long- term Investments		24.0
Level 2
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,887.4	2,246.5
Gross Unrealized Gains	5.3	10.0
Gross Unrealized Losses	(3.0)	(0.6)
Fair Value	1,889.7	2,255.9
Cash and Cash Equivalents	35.2	75.9
Short- term Investments	592.4	615.3
Long- term Investments	1,262.1	1,564.7
Level 2 \| Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	121.9	157.4
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	121.9	157.4
Cash and Cash Equivalents	33.2	75.9
Short- term Investments	88.7	81.5
Long- term Investments	0.0	0.0
Level 2 \| Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	758.7	952.1
Gross Unrealized Gains	2.8	5.8
Gross Unrealized Losses	(1.7)	(0.4)
Fair Value	759.8	957.5
Cash and Cash Equivalents	0.0	0.0
Short- term Investments	235.8	274.6
Long- term Investments	524.0	682.9
Level 2 \| U.S. government agencies
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	425.0	636.9
Gross Unrealized Gains	1.0	2.6
Gross Unrealized Losses	(0.8)	0.0
Fair Value	425.2	639.5
Cash and Cash Equivalents	2.0	0.0
Short- term Investments	103.3	133.6
Long- term Investments	319.9	505.9
Level 2 \| Non-U.S. government securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	68.0	90.8
Gross Unrealized Gains	0.3	0.5
Gross Unrealized Losses	(0.2)	0.0
Fair Value	68.1	91.3
Cash and Cash Equivalents	0.0	0.0
Short- term Investments	41.4	21.8
Long- term Investments	26.7	69.5
Level 2 \| Municipal securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	513.8	409.3
Gross Unrealized Gains	1.2	1.1
Gross Unrealized Losses	(0.3)	(0.2)
Fair Value	514.7	410.2
Cash and Cash Equivalents	0.0	0.0
Short- term Investments	123.2	103.8
Long- term Investments	391.5	306.4
Level 3
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	8.0	8.0
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	(0.6)	(0.6)
Fair Value	7.4	7.4
Cash and Cash Equivalents	0.0	0.0
Short- term Investments	0.0	0.0
Long- term Investments	7.4	7.4
Level 3 \| Municipal securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	8.0	8.0
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	(0.6)	(0.6)
Fair Value	7.4	7.4
Cash and Cash Equivalents	0.0	0.0
Short- term Investments	0.0	0.0
Long- term Investments	$ 7.4	$ 7.4

FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-For-Sale Investments (Detail) $ in Millions	Sep. 30, 2013 USD ($)
Amortized Cost
Mature in less than one year, Amortized Cost	$ 1,028.6
Mature in one to five years, Amortized Cost	1,311.3
Mature in after five years, Amortized Cost	8.0
Total, Amortized Cost	2,347.9
Fair Value
Mature in less than one year, Fair Value	1,029.8
Mature in one to five years, Fair Value	1,312.0
Mature in after five years, Fair Value	7.4
Total, Fair Value	$ 2,349.2

FINANCIAL INSTRUMENTS - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange gains (losses) related to re-measurement	$ 2.4	$ 0.2	$ 1.0	$ (0.4)
Foreign Exchange Forward \| Interest and other income (expense), net \| Not Designated As Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Recognized gains (losses) in interest and other income, net	$ (2.6)	$ 0.0	$ (1.8)	$ 0.6

FINANCIAL INSTRUMENTS - Gross Notional Amounts for Outstanding Derivatives (Detail) € in Millions, ₩ in Millions, ¥ in Millions, £ in Millions, SFr in Millions	Sep. 30, 2013 CHF (SFr)	Sep. 30, 2013 EUR (€)	Sep. 30, 2013 GBP (£)	Sep. 30, 2013 JPY (¥)	Sep. 30, 2013 KRW (₩)	Dec. 31, 2012 CHF (SFr)	Dec. 31, 2012 EUR (€)	Dec. 31, 2012 GBP (£)	Dec. 31, 2012 JPY (¥)	Dec. 31, 2012 KRW (₩)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts		€ 36.9			₩ 1,800.0		€ 20.0			₩ 4,400.0
Foreign Exchange Forward \| Not Designated As Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	SFr 0.0	€ 31.6	£ 7.0	¥ 70.0	₩ 12,204.2	SFr 1.0	€ 37.6	£ 5.4	¥ 0.0	₩ 4,600.0

FINANCIAL INSTRUMENTS - Additional Information (Detail) € in Millions, $ in Millions, ₩ in Billions	3 Months Ended		9 Months Ended
	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2013 EUR (€)	Sep. 30, 2013 KRW (₩)	Sep. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)	Dec. 31, 2012 EUR (€)	Dec. 31, 2012 KRW (₩)	Dec. 31, 2012 USD ($)	Jun. 30, 2012 USD ($)	Dec. 31, 2011 USD ($)
Investments, All Other Investments [Abstract]
Net realized gains recognized on the sale of investments	$ 0.6		$ 0.7
Net realized losses recognized on the sale of investments		$ 0.2		$ 1.7
Accumulated other comprehensive income, net unrealized gains (losses) on investments, net of tax		$ 6.9		$ 6.9			$ 1.7	$ (2.8)			$ 6.2	$ 3.3	$ 1.1
Derivative liabilities							$ (3.0)				$ (2.7)
Notional amounts of outstanding currency forward contracts					€ 36.9	₩ 1.8			€ 20.0	₩ 4.4

BALANCE SHEET DETAILS - Details of Selected Balance Sheet Items (Detail) - USD ($) $ in Millions	Sep. 30, 2013	Dec. 31, 2012
Inventories:
Raw materials	$ 59.1	$ 41.2
Work-in-process	6.8	4.4
Finished goods	134.2	75.9
Total inventories	$ 200.1	$ 121.5

CONTINGENCIES - Additional Information (Detail)				9 Months Ended
CONTINGENCIES - Additional Information (Detail)	Aug. 10, 2011	Sep. 15, 2010 Defendant	Aug. 19, 2010 Defendant	Sep. 30, 2013 Plaintiff
Commitments and Contingencies [Line Items]
Time limit given to plaintiffs for filing amended complaint, days	30 days
Number of individual plaintiffs involved in product liability lawsuits \| Plaintiff				50
Minimum
Commitments and Contingencies [Line Items]
Statute of limitation period				3 months
Maximum
Commitments and Contingencies [Line Items]
Statute of limitation period				6 months
Himmel v. Smith et al.
Commitments and Contingencies [Line Items]
Number of individual defendants involved in lawsuit			14
Applebaum v. Guthart et al.
Commitments and Contingencies [Line Items]
Number of individual defendants involved in lawsuit		15

STOCKHOLDERS' EQUITY - Schedule of Stock Repurchase Activities (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Equity [Abstract]
Shares repurchased	1.8	0.3	2.6	0.4
Average price per share	$ 398.87	$ 495.09	$ 429.09	$ 497.28
Value of shares repurchased	$ 693.8	$ 169.8	$ 1,109.2	$ 185.1

STOCKHOLDERS' EQUITY - Components of Accumulated Other Comprehensive Income, Net of Tax (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Gains (Losses) on Hedge Instruments
Beginning balance	$ 0.6	$ 0.3	$ 0.0	$ 0.0
Other comprehensive income before reclassifications	(3.0)	(1.7)	(1.4)	(1.0)
Reclassified from accumulated other comprehensive income	0.5	0.2	(0.5)	(0.2)
Net current-period other comprehensive income	(2.5)	(1.5)	(1.9)	(1.2)
Ending balance	(1.9)	(1.2)	(1.9)	(1.2)
Unrealized Gains (Losses) on Available-for- Sale Securities
Beginning balance	(2.8)	3.3	6.2	1.1
Other comprehensive income before reclassifications	3.9	3.5	(5.4)	5.5
Reclassified from accumulated other comprehensive income	0.6	0.1	0.9	0.3
Net current-period other comprehensive income	4.5	3.6	(4.5)	5.8
Ending balance	1.7	6.9	1.7	6.9
Foreign Currency Translation Gains (Losses)
Beginning balance	0.1	0.0	0.4	(0.2)
Other comprehensive income before reclassifications	0.5	0.1	0.2	0.3
Reclassified from accumulated other comprehensive income	0.0	0.0	0.0	0.0
Net current-period other comprehensive income	0.5	0.1	0.2	0.3
Ending balance	0.6	0.1	0.6	0.1
Total
Beginning balance	(2.1)	3.6	6.6	0.9
Other comprehensive income before reclassifications	1.4	1.9	(6.6)	4.8
Reclassified from accumulated other comprehensive income	1.1	0.3	0.4	0.1
Net current-period other comprehensive income	2.5	2.2	(6.2)	4.9
Ending balance	$ 0.4	$ 5.8	$ 0.4	$ 5.8

STOCKHOLDERS' EQUITY - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions				1 Months Ended	2 Months Ended	3 Months Ended			9 Months Ended
	Sep. 16, 2013	Jul. 25, 2013	Mar. 20, 2013	Jul. 29, 2013	Sep. 11, 2013	Sep. 30, 2013	Sep. 16, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount		$ 779,000,000	$ 1,000,000,000.0
Remaining authorized amount of stock repurchases									$ 1,000,000,000
Payments for stock repurchase						$ 693,800,000		$ 169,800,000	$ 1,109,200,000	$ 185,100,000
Shares of common stock repurchased						1.8		0.3	2.6	0.4
Common Stock \| Open Market Stock Repurchase 2013
Equity, Class of Treasury Stock [Line Items]
Shares of common stock repurchased						0.5
Common Stock \| Goldman, Sachs & CO. \| ASR Program 2013
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount				$ 500,000,000
Payments for stock repurchase				$ 500,000,000
Shares of common stock repurchased	0.1			1.2			1.3
Stock repurchase. settlement price per share					$ 385.16
Common Stock and APIC
Equity, Class of Treasury Stock [Line Items]
Decrease of equity due to stock repurchased and retired						$ 57,400,000
Retained Earnings
Equity, Class of Treasury Stock [Line Items]
Decrease of equity due to stock repurchased and retired						$ 636,400,000

SHARE-BASED COMPENSATION - Summary Of Stock Option Activity Under All Stock Plans (Detail) shares in Millions	9 Months Ended
	Sep. 30, 2013 $ / shares shares
Shares Available for Grant
Beginning balance, Shares Available for Grant	1.7
Options authorized, Shares Available for Grant	1.6
Options granted, Shares Available for Grant	(1.5)
Options exercised , Shares Available for Grant	0.0
Options forfeited/expired, Shares Available for Grant	0.1
Ending balance, Shares Available for Grant	1.9
Number Outstanding
Beginning balance, Number Outstanding	4.8
Options authorized, Number Outstanding	0.0
Options granted, Number Outstanding	1.5
Options exercised, Number Outstanding	(0.4)
Options forfeited/expired, Number Outstanding	(0.2)
Ending balance, Number Outstanding	5.7
Weighted Average Exercise Price Per Share
Beginning balance, Weighted Average Exercise Price Per Share \| $ / shares	$ 340.83
Options authorized, Weighted Average Exercise Price Per Share \| $ / shares	0.00
Options granted, Weighted Average Exercise Price Per Share \| $ / shares	473.68
Options exercised, Weighted Average Exercise Price Per Share \| $ / shares	253.53
Options forfeited/expired, Weighted Average Exercise Price Per Share \| $ / shares	456.31
Ending balance, Weighted Average Exercise Price Per Share \| $ / shares	$ 379.15

SHARE-BASED COMPENSATION - Stock-Based Compensation Expense (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	$ 50.4	$ 47.3	$ 127.3	$ 115.0
Income tax benefit	16.5	14.9	41.1	36.0
Share-based compensation expense after income taxes	33.9	32.4	86.2	79.0
Total cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	8.8	8.4	22.7	20.2
Total cost of sales \| Cost of sales - products
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	5.2	4.3	13.2	10.6
Total cost of sales \| Cost of sales - services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	3.6	4.1	9.5	9.6
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	30.6	28.2	76.6	69.7
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	$ 11.0	$ 10.7	$ 28.0	$ 25.1

SHARE-BASED COMPENSATION - Schedule Of Estimated Fair Value Of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend rate	0.00%	0.00%	0.00%	0.00%
Average risk free interest rate	1.50%	0.80%	1.20%	0.80%
Average expected term (in years)	4 years 6 months	4 years 1 month 6 days	4 years 6 months	4 years 3 months 18 days
Average expected volatility	31.00%	35.00%	30.00%	33.00%
Weighted average fair value at grant date	$ 110.81	$ 148.05	$ 126.87	$ 145.60
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend rate	0.00%	0.00%	0.00%	0.00%
Average risk free interest rate	0.20%	0.20%	0.20%	0.20%
Average expected term (in years)	1 year 3 months	1 year 3 months	1 year 3 months	1 year 3 months
Average expected volatility	35.00%	32.00%	34.00%	32.00%
Weighted average fair value at grant date	$ 115.84	$ 143.36	$ 153.33	$ 138.61

SHARE-BASED COMPENSATION - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	May 31, 2013	Apr. 25, 2013	Mar. 31, 2013	Jan. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable, number of shares	3,100,000		3,100,000
Options exercisable, weighted-average exercise price per share	$ 312.11		$ 312.11
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Stock Purchase Plan, shares purchased by employees	37,700	47,600	92,200	96,800
Employee Stock Purchase Plan, value of shares purchased by employees	$ 12.4	$ 13.9	$ 28.8	$ 27.8
Amended and Restated 2009 Employment Commencement Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock authorized					1,155,000			855,000	730,000
Amended and Restated 2010 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock authorized						4,850,000	3,650,000

INCOME TAXES - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Income tax expense	$ 21.3	$ 32.4	$ 151.6	$ 160.4
Income tax expense, percentage of pre-tax income	12.00%	15.00%	23.10%	25.00%
Federal statutory tax rate	35.00%	35.00%	35.00%
Discrete benefit related to previously unrecognized tax benefits	$ 26.2	$ 35.1
Discrete net benefit related to 2012 federal research and development			$ 7.5
Total gross unrecognized tax benefits	77.6		77.6		$ 88.0
Unrecognized tax benefits, period increase (decrease)			10.4
Unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate	76.0		76.0
Gross interest related to unrecognized tax benefit accrued	$ 1.9		1.9		$ 3.2
Unrecognized tax benefits increase in accrued interest			$ 1.3

NET INCOME PER SHARE - Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share, Basic and Diluted [Abstract]
Net income	$ 156.8	$ 183.3	$ 504.8	$ 481.7
Weighted-average shares outstanding used in basic calculation	38.6	39.9	39.6	39.8
Add: Dilutive effect of potential common shares	0.7	1.2	0.9	1.3
Weighted-average shares used in computing diluted net income per share	39.3	41.1	40.5	41.1
Net income per share:
Basic (in dollars per share)	$ 4.06	$ 4.59	$ 12.75	$ 12.10
Diluted (in dollars per share)	$ 3.99	$ 4.46	$ 12.46	$ 11.72

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

NET INCOME PER SHARE - Additional Information (Detail) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]
Employee stock options excluded from computation of diluted net income per share	2.6	1.1	2.1	0.8